Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Early Parkinson Disease (Early PD) Clear all
Completed No phase listed Observational

Measures of Motor Impairment in Early Parkinson's Disease

NCT00291265
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 7, 2026, 5:17 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700
View directory record Official record
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
63
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 5:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Early Parkinson's Disease (PD) Cross-Sectional

NCT00817453
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 7, 2026, 5:17 AM EDT
Not yet recruiting Phase 1 Interventional

AAV2-hAADC for Parkinson's Disease (PDCS-01)

NCT07267065
View directory record Official record
Conditions
Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Not applicable Interventional

Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease

NCT05308238
View directory record Official record
Conditions
Parkinson Disease
Interventions
Occupational therapy intervention group, Disease management education group
Behavioral
Lead sponsor
San Jose State University
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Jose, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

NCT04524351
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Safety of Urate Elevation in Parkinson's Disease

NCT00833690
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, inosine
Drug
Lead sponsor
The Parkinson Study Group
Network
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Results available

Flexible-Dose Trial in Early Parkinson's Disease (PD)

NCT04223193
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Fresno, California • Boca Raton, Florida • Maitland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186
View directory record Official record
Conditions
Early-stage Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 7, 2026, 5:17 AM EDT
Terminated No phase listed Observational

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

NCT00804479
View directory record Official record
Conditions
Parkinson's Disease
Interventions
No intervention.
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 7, 2026, 5:17 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Study to Analyze Symptoms Prevalent in Early PD (Dysphonia, Tremor)

NCT04288804
View directory record Official record
Conditions
Parkinson Disease
Interventions
Smartphone microphone sensor, Smartphone accelerometer sensor
Device
Lead sponsor
Goalspal LLC
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Results available

Fixed-Dose Trial in Early Parkinson's Disease (PD)

NCT04201093
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Results available

Study of Urate Elevation in Parkinson's Disease, Phase 3

NCT02642393
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 2 Interventional

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

NCT01060878
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 7, 2026, 5:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease

NCT03043768
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
GWT-TUD GmbH
Other
Eligibility
35 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 7, 2026, 5:17 AM EDT
Completed No phase listed Observational

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

NCT05699460
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
Interventions
This is an observational study.
Other
Lead sponsor
AskBio Inc
Industry
Eligibility
35 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 7, 2026, 5:17 AM EDT
Completed No phase listed Observational

Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)

NCT00104585
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 7, 2026, 5:17 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients

NCT06975059
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
NUSHU shoe
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 7, 2026, 5:17 AM EDT
Not listed Phase 1 Interventional

Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD)

NCT04922190
View directory record Official record
Conditions
Parkinson Disease
Interventions
Physical Activity Coaching
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 4 Interventional Results available

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mirapex, Requip
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 7, 2026, 5:17 AM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

NCT00335374
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 7, 2026, 5:17 AM EDT
Not listed Phase 1 Interventional

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

NCT02579473
View directory record Official record
Conditions
Parkinson's Disease
Interventions
SER-214
Drug
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Hallandale, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 7, 2026, 5:17 AM EDT